Story perspectives

Study Reveals Mass Spectrometry Boosts Drug Target Reliability

12/2/2025

Summary

Story summary

Seer, Inc. published Nature Genetics findings from a genome-wide association study led by Dr. Karsten Suhre, analyzing about 1,600 samples.
The study used mass spectrometry-based proteomics and found that about one-third of affinity-based associations may not replicate.
The Proteograph Product Suite enabled peptide-level resolution and identified 364 pQTLs, with 102 replicated.
The findings show mass spectrometry can distinguish true biological effects from artifacts, boosting drug target and biomarker reliability.

1 of 1

Story summary

Seer, Inc. published Nature Genetics findings from a genome-wide association study led by Dr. Karsten Suhre, analyzing about 1,600 samples.
The study used mass spectrometry-based proteomics and found that about one-third of affinity-based associations may not replicate.
The Proteograph Product Suite enabled peptide-level resolution and identified 364 pQTLs, with 102 replicated.
The findings show mass spectrometry can distinguish true biological effects from artifacts, boosting drug target and biomarker reliability.